The Substance Use Research Unit investigates pharmacologic and behavioral interventions to maximize the health outcomes of people who use alcohol, methamphetamine, opioids, and other substances. Our work has an emphasis in the reduction of HIV transmission and the prevention of opioid overdose. Our studies target active substance users and are developed with the principles of harm reduction.
Say When is a randomized controlled trial to evaluate whether naltrexone treatment helps to reduce alcohol consumption among MSM.
The SEEDS study was a cross-sectional, behavioral study that used respondent-driven sampling (RDS) to recruit participants to learn more about patterns of alcohol use among men who have sex with men (MSM).
M2 is a randomized controlled trail to evaluate if mirtazapine (Remeron) helps to reduce meth use among MSM.
REBOOT was a pilot randomized controlled trial to determine the feasibility and acceptability of a repeated-dose brief intervention to reduce overdose and risk behaviors among naloxone recipients. REBOOT reduced opioid overdose events more than information and referrals.
TREX was a controlled trail which enrolled participants who received naltrexone for extended release injectable suspension. The goal of this study was to see if this medication helps to reduce meth use.
A San Francisco research study using a medication to reduce alcohol and meth use.
Project HOPE is a multi-site, NIH-funded study within the NIDA Clinical Trials Network (CTN); San Francisco DPH led the clinical and intervention team for the trial, although the trial did not take place in San Francisco and the Principal Investigator was Dr Lisa Metsch. Project HOPE sought to address issues around HIV-infected persons who delay seeking care until their […]
The purpose of this study was to encourage health care providers to evaluate high risk HIV transmission behaviors and offer prevention messages to their HIV-positive patients.
Bump: Aripiprazole was a randomized, double-blind, placebo-controlled trial of the medication aripiprazole for methamphetamine-using individuals, including MSM, and assessed efficacy, acceptability, tolerability, safety, and adherence to study medication.
Project MIX was a multi-site, six session behavioral intervention for substance using MSM. Men could be HIV-positive or negative, and more than half were African American or Latino. Participants were randomized to participate in the intervention sessions or video discussion groups, and were compared against a third group who received standard HIV testing and counseling. […]
BUMP: Mirtazapine was a randomized controlled trial that assessed the efficacy of mirtazapine in reducing methamphetamine use among high-risk MSM.
BUMP: Bupropion was a pilot sudy to determine the feasibility enrolling and retaining meth-dependent MSM into a pharmacologic study of bupropion vs. placebo and measuring the tolerability of and adherence to medication among these participants.
Project Aware was an NIH-funded, clinical trial in which individuals at STD clinics were asked to participate in a HIV testing and counseling study. This study explored whether the provision of counseling reduced risk behavior and sexually transmitted infections over time. 5012 participants at 9 STD clinics throughout the United States were randomized to […]
CTN 032 found that participants in the two groups offering in-house testing were more likely to be tested and receive results than participants randomized into the off-site testing group.
The “BUMP” studies are designed to determine if medications can help individuals who use meth to stop or decrease their meth use and reduce the associated HIV risk behaviors.
In this street-based survey, 89 meth using MSM were asked details about their most recent meth use episode, including who they used with, their relationship with others they used with, where they used, and their sexual activity while on meth.